Fig. 1

Prevalence of patients meeting the criteria for metabolic syndrome in the SURPASS clinical trial program. Data are proportion of patients with at least 3 diagnostic criteria for metabolic syndrome at the primary endpoint of 40/52 weeks. Pooled tirzepatide vs comparator was statistically significant in each trial. MET: metformin; SGLT2i: sodium-glucose co-transporter 2 inhibitor; SU: sulfonylurea